Bionaturis Group company expert in the use of zebrafish as alternative animal model, Biobide, will present new studies about the versatility of this specie for toxicity, security and efficacy assays of new compounds in the 10th European Zebrafish Meeting in Budapest. The event -held from 3 to 7th, June- will gather the specialists of this increasing sector.
Bionaturis Group representatives will showcase the biotechnological group offer in two relevant events in USA in June: the World Preclinical Congress (Boston) and the Bio International Convention (San Diego).
R&D Management Director and co-founder of BBD BioPhenix-Biobide (part of Bionaturis Group), Arantza Muriana, has been honoured with the prize Business Manager of the Year in Guipuzcoa by the Professional and Business Women Association from Guipuzcoa, Aspegi (in Spanish).
Biobide Signs a contract with the U.S. National Institute of Environmental Health Sciences (NIH-NIEHS)
Bionaturis (ticker BNT-MAB), an international reference company developing biological drugs, has just acquired the San Sebastian-based company BBD BIOPHENIX S.L (BBD), a leader in state-of-the-art screening systems for drug discovery. With this acquisition Bionaturis incorporates cutting-edge biotech assets to its organic growth, in this case, related to the use of zebra fish models for early determination of drug pharmacological profiles.
